It appears that I may be in the minority, but I am now increasing the % I am assigning to a successful outcome of the Rida Phase 111 to 75% success vs 25% failure for the following reasons:
1- The exceptional science at Ariad
2- The Phase 11 numbers
3- Merck (both their confidence in the drug and their experience in getting drugs approved)
4- The action in the stock over the past few weeks:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.